ECRI Horizon Scanning has selected the topics below as those with potential for impact relative to COVID-19 in the United States within the next 12 months. All views presented are preliminary and based on readily available information at the time of writing.

Because these topics are rapidly developing, we cannot guarantee the accuracy of this information after the date listed on this publication. In addition, all views expressed in the commentary section are solely those of ECRI Horizon Scanning and have not been vetted by other stakeholders. Topics are listed in alphabetical order.

Description

Baricitinib for use in combination with remdesivir received an EUA from the FDA on November 19, 2020. The EUA defines its use for treating COVID-19 in hospitalized adult and pediatric patients requiring respiratory support, including supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation. The EUA decision was based on data reported by the developer from the ACTT-2 trial, which demonstrated that patients taking the drug combination, compared with remdesivir alone, experienced improved recovery time​​ (7 versus 8 days), better clinical status at day 15, lower progression to ventilation (23% versus 28%), and ​decreased death (4.7% versus 7.1%). 

Baricitinib and remdesivir constitute the first combination therapy to receive an EUA from the FDA for COVID-19. ​Baricitinib is an oral Janus kinase inhibitor intended to reduce inflammation in COVID by blocking a proinflammatory signaling pathway. It is FDA-approved to treat moderate to severe rheumatoid arthritis. It is the first drug acting on an inflammatory pathway in the body to receive an EUA for COVID-19. Remdesivir is an intravenous antiviral that the FDA approved on October 22, 2020, to treat patients hospitalized with COVID-19​ and works by inhibiting replication of the novel coronavirus.

Based on available dosing information and pricing, up to 14 days of treatment with baricitinib costs about $2200. Based on prescribing information and pricing, up to 10 days of treatment with remdesivir costs about $6100, making the cost of a single course of the combined regimen up to $8300.

Commentary

Baricitinib and remdesivir together is the first combination treatment for COVID-19 to receive an EUA from the FDA. It combines primary anti-inflammatory and antiviral mechanisms of action and might treat patients with severe disease better than a single mechanism alone. However, some experts have questioned the appropriateness of adding baricitinib to remdesivir instead of dexamethasone given the cost and efficacy data available.  

Early feedback from ECRI internal stakeholders commenting on this topic thought that, although the drug combination’s results might be incremental to remdesivir alone, it is arriving at a critical time. Hospitals are overcrowded nationwide. Reduced mortality risk combined with a 1-day earlier hospital discharge or 1 fewer patient who needs mechanical ventilation would likely make a difference in population health outcomes and decrease the burden on the health care system during this critical surge. Additionally, effective COVID-19 treatments will still be needed during and after widespread distribution and administration of COVID-19 vaccines. Combination baricitinib and remdesivir is a relatively inexpensive treatment that might help bridge the gap. However, stakeholders warned that limited supply and access to baricitinib might lead to disparities. 

• Category: Treatments
• Areas of potential impact: Patient outcomes, health care delivery and process, health care costs

Description

As the COVID-19 pandemic continues, many underserved and rural communities, as well as COVID-19 hotspots around the United States, still face challenges surrounding access to testing and treatment. An estimated 2000 mobile clinics, customized motor vehicles that travel to communities to provide health care, are active in the United States. These mobile clinics might help meet demand for COVID-19 health services.

In addition to existing mobile clinic infrastructure, companies are offering mobile clinics for rent or sale. For example, Aardvark Mobile Health vehicles (Aardvark Mobile Tours, LLC, Conshohocken, Pennsylvania) offers mobile health trucks that are equipped with proper positive and negative air pressure and the ability to become CLIA certified up to biosafety level 2. The vehicles can be used for rapid testing, vaccinations, and health screenings. The easily sterilized areas and partitions, which separate the nurses conducting the tests from the individuals receiving them, help maintain the safety of all those involved. Two to 4 testing windows allow nurses to give up to 400 tests a day, similar to drive-thru testing facilities, which are inaccessible to people relying on public transportation.  

Commentary

Mobile health clinics might increase access to COVID-19 testing in underserved hot spots and rural communities. Ease of movement and set-up of mobile testing might improve implementation of testing initiatives in scattered or harder-to-reach populations. 

Early feedback from ECRI internal stakeholders suggested that mobile health clinics might greatly benefit rural areas where COVID-19 cases are surging and health facilities are lacking. Accessible care could reduce health care disparities and costs by increasing diagnostic care, allowing earlier intervention in the disease course. Stakeholders noted that although these clinics might improve accessibility to care, the usability of mobile clinics hinges on the availability of health care workers to staff these units, given the current health care staff shortages and burnout, even in highly populated regions. Also, economic incentives or resistance to unconventional medical care in rural areas might promote the use of mobile health units in urban areas, increasing disparities in rural areas.  

• Categories: Systems and management
• Areas of potential impact: Patient outcomes, population health, health care delivery and process, clinician and/or caregiver safety